drugset / Trial / NCT00685841

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841

Phase 3 Completed 717 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.

Timeline

Start
2002-02
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 15 ug Inhaled
Subject Arformoterol Small molecule 25 ug Inhaled
Subject Arformoterol Small molecule 50 ug Inhaled
Comparator Salmeterol Other / unclassified 42 ug Inhaled